Inclusion criteria in BE studies [Design Issues]

posted by BEQool  – 2023-05-05 12:42 (739 d 10:10 ago) – Posting: # 23543
Views: 3,828
(edited on 2023-05-05 12:52)

❝ Just wish to mention that Gender is a between-subject factor (at least for most practical purposes ex-Thailand), so there is no particular gain in including Gender as a factor when you have Subject in the model unless there is a specific regulatory requirement.


Hello,
maybe a stupid question but is Gender*Treatment also a between-subject factor (like Sequence and Gender here)?
In the article Evaluation of sex-by-formulation interaction in bioequivalence studies of efavirenz tablets by González-Rojano et al. it doesnt say anything about which factor they used (within- or between-subject) to test Gender*Treatment interaction.

Additionally, how do you know which factor is a within-subject and which is a between-subject? If anyone has an explanation in simple words :-)

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
176 visitors (0 registered, 176 guests [including 10 identified bots]).
Forum time: 22:52 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5